Wall Street analysts predict that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will post sales of $14.85 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Alnylam Pharmaceuticals’ earnings. The highest sales estimate is $25.20 million and the lowest is $5.86 million. Alnylam Pharmaceuticals posted sales of $37.92 million in the same quarter last year, which suggests a negative year-over-year growth rate of 60.8%. The business is scheduled to report its next quarterly earnings results on Thursday, February 14th.
According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full year sales of $69.64 million for the current financial year, with estimates ranging from $59.74 million to $81.17 million. For the next fiscal year, analysts forecast that the company will post sales of $148.20 million, with estimates ranging from $81.55 million to $190.86 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($0.41). Alnylam Pharmaceuticals had a negative net margin of 754.13% and a negative return on equity of 43.07%. The business had revenue of $2.07 million during the quarter, compared to the consensus estimate of $22.66 million. During the same quarter last year, the company posted ($1.34) EPS. The firm’s revenue was down 87.9% on a year-over-year basis.
ALNY traded up $1.18 during trading hours on Tuesday, reaching $72.66. The company’s stock had a trading volume of 858,900 shares, compared to its average volume of 916,918. Alnylam Pharmaceuticals has a 52 week low of $63.57 and a 52 week high of $153.99. The company has a current ratio of 11.05, a quick ratio of 10.96 and a debt-to-equity ratio of 0.02. The stock has a market cap of $7.39 billion, a PE ratio of -13.41 and a beta of 2.54.
In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 2,500 shares of the stock in a transaction on Thursday, August 30th. The stock was sold at an average price of $120.00, for a total transaction of $300,000.00. Following the transaction, the chief operating officer now owns 1,916 shares in the company, valued at approximately $229,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.70% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. grew its holdings in shares of Alnylam Pharmaceuticals by 8.2% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 268,111 shares of the biopharmaceutical company’s stock worth $26,406,000 after purchasing an additional 20,357 shares in the last quarter. Riverhead Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 195.6% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,365 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 1,565 shares in the last quarter. Advisors Asset Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 269.8% during the 2nd quarter. Advisors Asset Management Inc. now owns 54,368 shares of the biopharmaceutical company’s stock worth $1,674,000 after purchasing an additional 39,665 shares in the last quarter. Amalgamated Bank grew its holdings in shares of Alnylam Pharmaceuticals by 11.3% during the 2nd quarter. Amalgamated Bank now owns 20,420 shares of the biopharmaceutical company’s stock worth $2,011,000 after purchasing an additional 2,080 shares in the last quarter. Finally, NumerixS Investment Technologies Inc acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $398,000. 90.63% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Further Reading: How do investors use RSI to grade stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.